Cebix Announces Positive Results of ERSATTA™ Phase 1/2 Trial Targeting Peripheral Neuropathy in Type 1 Diabetics

Cebix Announces Positive Results of ERSATTA™ Phase 1/2 Trial Targeting Peripheral Neuropathy in Type 1 Diabetics PR Newswire LA JOLLA, California, Oct. 17, 2012 - $30.9M Series B Investment closed and Joel Martin appointed as President and CEO LA JOLLA, California, Oct. 17, 2012 /PRNewswire/ -- Cebix Incorporated, a biopharmaceutical company developing treatments for complications of diabetes, today announced results of a Phase 1/2 trial of its lead investigational drug, ERSATTA™ in peripheral neuropathy. ERSATTA is the first once-weekly C-peptide therapy to target loss of nerve function and other vascular complications in type 1 diabetes patients. The successful 72 subject trial, which focused on safety, tolerability, and pharmacokinetics, demonstrated that ERSATTA was well tolerated, with no serious adverse effects over a twelve week period. The pharmacokinetic profile supports convenient, once weekly dosing. The trial further demonstrated a favorable efficacy signal in type 1 diabetic patients who self-injected ERSATTA once weekly over the 12-week period. Both the safety and efficacy results were consistent with results from prior published clinical trials of native C-peptide. Top line results of the ERSATTA study were presented on October 4th, 2012 at the Annual Meeting of the European Association for the Study of Diabetes (abstract #1110). In parallel with the successful completion of the trial, the company also announced the closing of a $30.